NASDAQ : BBLG
Bone Biologics Corporation — Key statistics
Healthcare · Biotechnology · United States
Last price 0.3883 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.07M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.26M |
| Enterprise Value | -4.83M |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 26, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 3.39M |
| Shares Outstanding | 3.39M |
| Shares Change (YoY) | +176.02% |
| Shares Change (QoQ) | +108.00% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 4.33% |
| Float | 3.39M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.21 |
| P/TBV Ratio | 0.21 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 13.38 |
| Quick Ratio | 12.68 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -47.49% |
| Return on Assets (ROA) | -29.46% |
| Return on Invested Capital (ROIC) | -31.46% |
| Return on Capital Employed (ROCE) | -50.62% |
| Weighted Average Cost of Capital (WACC) | 7.41% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.42M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.57 |
| 52-Week Price Change | -82.59% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 1.06 |
| Relative Strength Index (RSI) | 30.51 |
| Average Volume (20 Days) | 39,335 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 22,777 |
| Short Previous Month | 49,512 |
| Short % of Shares Out | 0.67% |
| Short % of Float | 0.67% |
| Short Ratio (days to cover) | 0.08 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -3.01M |
| Pretax Income | -2.84M |
| Net Income | -2.84M |
| EBITDA | n/a |
| EBIT | -3.01M |
| Earnings Per Share (EPS) | -$1.24 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 6.09M |
| Total Debt | n/a |
| Net Cash | 6.09M |
| Net Cash Per Share | $1.80 |
| Equity (Book Value) | 5.95M |
| Book Value Per Share | 1.76 |
| Working Capital | 5.95M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -2.57M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -2.57M |
| FCF Per Share | -$0.76 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -176.02% |
| Shareholder Yield | -176.02% |
| Earnings Yield | -335.43% |
| FCF Yield | -204.46% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 10, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |